Fig. 3
MYC inhibition with FPPa-OmoMYC confers therapeutic effect in a tumor allograft model in mice. a Left: Tumor volumes during the treatment phase of mice treated with vehicle, FPPa-OmoMYC, OmoMYC, and FPPa. Black arrows indicate injections. Right: Tumor volumes during the post-treatment phase. T11 cells stably expressing the luciferase gene were obtained using a retroviral expression vector. Retroviral particles were produced in HEK293T GAG-POL cells transfected with the retroviral packaging plasmids VSV-G. T11 cells were freshly infected with the supernatants a total of four times. All experimental animal work was performed in accordance with the Animal Ethics Committee of the University of Western Australia. Female BALB/cJ mice at 4 weeks of age were purchased from the Animal Resources Centre (WA, Australia). 2.5 × 105 T11 cells were resuspended in 1:1 serum-free media: Matrigel (BD Bioscience, NSW, Australia) and injected subcutaneously into the flank. Once tumors reached 50 mm [3], 12 mice were randomly assigned for each group: vehicle (PBS), FPPa, OmoMYC, and FPPa-OmoMYC. 40 nmoles of peptides were intratumorally injected every two days for a total of four times. Tumors were measured by digital caliper and tumor volumes calculated with the formula: V = 0.5 × L × W2. Mice were sacrificed when the tumors were >800 mm3. b Percentage of mice with tumors < 800 mm3. c Images of H&E, Ki-67, PD-L1, and TUNEL stainings of representative allografts derived from vehicle, FPPa-OmoMYC, OmoMYC, and FPPa treated mice at day 12. H&E, Ki-67, PD-L1 (Abcam, ab174838), and TUNEL stainings in the tumors were performed as described [27]. Images are at 40× magnification. *, ** and *** represent p < 0.05, p < 0.005 and p < 0.0005 respectively, relative to FPPa-OmoMYC treated group
